Table 2.
Summary of adverse events (AEs)
| AEs | Placebo (N=6) | Evogliptin 5 mg (N=8) | Evogliptin 10 mg (N=8) | Evogliptin 20 mg (N=8) |
|---|---|---|---|---|
|
| ||||
| Number of cases (% of subjects with AEs in a group)
| ||||
| 1 (25) | 10 (50) | 5 (50) | 4 (37.5) | |
| Epigastric discomfort | – | 1 | 1a | – |
| Oral mucosa erosion | 1 | – | – | – |
| Fatigue | – | 1a | – | |
| Sweating | – | 1 | 1a | – |
| Prurigo | – | – | – | 1 |
| Pharyngitis | – | – | 1 | – |
| Sputum | – | – | – | – |
| Musculoskeletal discomfort | – | – | 1 | – |
| Joint pain | – | – | – | 1 |
| Headache | – | – | – | 1a |
| Vasovagal syncope | – | 1 | – | – |
| Insomnia | – | 1a | – | – |
| Poor-quality sleep | – | 1 | – | – |
| Eyeball pain | – | 1 | – | – |
| Cough | – | 1 | – | – |
| Rhinorrhea | – | 1 | – | – |
| Throat irritation | – | 1 | – | – |
| Increased urinary frequency | – | – | – | 1a |
Notes:
a
These cases were judged to be related to the study drug. Unreported cases are represented by –.